Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.

doi:10.1158/2159-8290.CD-20-0487

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.

Cancer discovery - 1 Jan 2021

Grunewald Susanne, Klug Lillian R, Mühlenberg Thomas, Lategahn Jonas, Falkenhorst Johanna, Town Ajia, Ehrt Christiane, Wardelmann Eva, Hartmann Wolfgang, Schildhaus Hans-Ulrich, Treckmann Juergen, Fletcher Jonathan A, Jung Sascha, Czodrowski Paul, Miller Stephen, Schmidt-Kittler Oleg, Rauh Daniel, Heinrich Michael C, Bauer Sebastian

Abstract excerpt

Gastrointestinal stromal tumors (GIST) harboring activating mutations of PDGFRA respond to imatinib, with the notable exception of the most common mutation, D842V. Avapritinib is a novel, potent KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date, only a minority of PDGFRA-mutant patients treated with avapritinib have developed secondary resistance. Tumor and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastric Cancer Management and Outcomes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Gastrointestinal Tumor Research and Treatment

Share to Mutation

Share to Pyrazoles

Share to Pyrroles

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Triazines

Source

Open in PubMed

Identifiers

PMID: 32972961
DOI: 10.1158/2159-8290.CD-20-0487

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.PMID 32972961Read ↗

Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.Semantic proximity Read ↗

The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)Semantic proximity Read ↗

An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumorsSemantic proximity Read ↗

Avapritinib: First Approval.Semantic proximity Read ↗

Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.Semantic proximity Read ↗

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.Semantic proximity Read ↗

KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.Semantic proximity Read ↗

Avapritinib for metastatic or unresectable gastrointestinal stromal tumors.Semantic proximity Read ↗

[Molecular mechanisms of primary and secondary resistance, molecular-genetic features and characteristics of KIT/PDGFRA non-mutated GISTs].Semantic proximity Read ↗

Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor.Semantic proximity Read ↗

Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.Semantic proximity Read ↗

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.